Allianz Asset Management Gmb H Prothena Corp Public LTD CO Transaction History

Allianz Asset Management Gmb H

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$47.3 - $70.6 $425,700 - $635,400	-9,000 Reduced 56.96%	6,800 $328,000
Q2 2023 Aug 11, 2023	BUY	$48.26 - $78.59 $521,208 - $848,772	10,800 Added 216.0%	15,800 $1.08 Million
Q1 2023 May 11, 2023	BUY	$46.97 - $58.27 $234,850 - $291,350	5,000 New	5,000 $242,000
Q2 2022 Aug 12, 2022	SELL	$22.73 - $39.98 $61,371 - $107,945	-2,700 Reduced 16.27%	13,895 $377,000
Q4 2021 Feb 11, 2022	BUY	$42.11 - $73.26 $698,815 - $1.22 Million	16,595 New	16,595 $815,000
Q2 2020 Aug 14, 2020	SELL	$9.56 - $12.51 $169,288 - $221,527	-17,708 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$7.54 - $15.77 $133,518 - $279,255	17,708 New	17,708 $189,000
Q4 2017 Feb 13, 2018	SELL	$35.44 - $63.76 $232,486 - $418,265	-6,560 Closed	0 $0
Q2 2017 Aug 14, 2017	SELL	N/A	-997 Reduced 13.19%	6,560 $355,000
Q1 2017 Apr 17, 2019	SELL	N/A	-2,071 Reduced 21.51%	7,557 $422,000
Q4 2016 Apr 17, 2019	SELL	N/A	-21,715 Reduced 69.28%	9,628 $474,000
Q3 2016 Apr 17, 2019	BUY	N/A	31,343	31,343 $1.88 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.